| 1RV1 | A:; B:; C: | CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN IMIDAZOLINE INHIBITOR |
| 1T4E | A:; B: | STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH A BENZODIAZEPINE INHIBITOR |
| 1T4F | M: | STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH AN OPTIMIZED P53 PEPTIDE |
| 1YCR | A: | MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53 |
| 2AXI | A:25-109 | HDM2 IN COMPLEX WITH A BETA-HAIRPIN |
| 2GV2 | A: | MDM2 IN COMPLEX WITH AN 8-MER P53 PEPTIDE ANALOGUE |
| 2LZG | A: | NMR STRUCTURE OF MDM2 (6-125) WITH PIP-1 |
| 3G03 | A:; C: | STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH HIGH AFFINITY PEPTIDE |
| 3JZK | A: | CRYSTAL STRUCTURE OF MDM2 WITH CHROMENOTRIAZOLOPYRIMIDINE 1 |
| 3JZR | A: | HUMAN MDM2 LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDI6W) |
| 3JZS | A: | HUMAN MDM2 LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDIQ) |
| 3LBK | A: | STRUCTURE OF HUMAN MDM2 PROTEIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR |
| 3LBL | A:; C:; E: | STRUCTURE OF HUMAN MDM2 PROTEIN IN COMPLEX WITH MI-63-ANALOG |
| 3TJ2 | A:; C: | STRUCTURE OF A NOVEL SUBMICROMOLAR MDM2 INHIBITOR |
| 3TU1 | A: | EXHAUSTIVE FLUORINE SCANNING TOWARDS POTENT P53-MDM2 ANTAGONIST |
| 3V3B | A:; B: | STRUCTURE OF THE STAPLED P53 PEPTIDE BOUND TO MDM2 |
| 3VBG | A:; B:; C:; D: | STRUCTURE OF HDM2 WITH DIMER INDUCING INDOLYL HYDANTOIN RO-2443 |
| 3VZV | A:; B: | CRYSTAL STRUCTURE OF HUMAN MDM2 WITH A DIHYDROIMIDAZOTHIAZOLE INHIBITOR |
| 3W69 | A:; B: | CRYSTAL STRUCTURE OF HUMAN MDM2 WITH A DIHYDROIMIDAZOTHIAZOLE INHIBITOR |
| 4DIJ | A:; B: | THE CENTRAL VALINE CONCEPT PROVIDES AN ENTRY IN A NEW CLASS OF NON PEPTIDE INHIBITORS OF THE P53-MDM2 INTERACTION |
| 4ERE | A:; B: | CRYSTAL STRUCTURE OF MDM2 (17-111) IN COMPLEX WITH COMPOUND 23 |
| 4ERF | A:; C:; E: | CRYSTAL STRUCTURE OF MDM2 (17-111) IN COMPLEX WITH COMPOUND 29 (AM-8553) |
| 4HBM | A:; B:; C:; D:; E:; F:; G:; H: | ORDERING OF THE N TERMINUS OF HUMAN MDM2 BY SMALL MOLECULE INHIBITORS |
| 4HG7 | A: | CRYSTAL STRUCTURE OF AN MDM2/NUTLIN-3A COMPLEX |
| 4JV7 | A: | CO-CRYSTAL STRUCTURE OF MDM2 WITH INHIBITOR (2S,5R,6S)-2-BENZYL-5,6-BIS(4-BROMOPHENYL)-4-METHYLMORPHOLIN-3-ONE |
| 4JV9 | A: | CO-CRYSTAL STRUCTURE OF MDM2 WITH INHIBITOR (2S,5R,6S)-2-BENZYL-5,6-BIS(4-CHLOROPHENYL)-4-METHYLMORPHOLIN-3-ONE |
| 4JVE | A: | CO-CRYSTAL STRUCTURE OF MDM2 WITH INHIBITOR (2R,3E)-2-[(2S,3R,6S)-2,3-BIS(4-CHLOROPHENYL)-6-(4-FLUOROBENZYL)-5-OXOMORPHOLIN-4-YL]PENT-3-ENOIC ACID |
| 4JVR | A:; C:; E: | CO-CRYSTAL STRUCTURE OF MDM2 WITH INHIBITOR (2'S,3R,4'S,5'R)-N-(2-AMINOETHYL)-6-CHLORO-4'-(3-CHLORO-2-FLUOROPHENYL)-2'-(2,2-DIMETHYLPROPYL)-2-OXO-1,2-DIHYDROSPIRO[INDOLE-3,3'-PYRROLIDINE]-5'-CARBOXAMIDE |
| 4JWR | A:; B:; C: | CO-CRYSTAL STRUCTURE OF MDM2 WITH INHIBITOR {(2S,5R,6S)-6-(3-CHLOROPHENYL)-5-(4-CHLOROPHENYL)-4-[(2S)-1-HYDROXYBUTAN-2-YL]-3-OXOMORPHOLIN-2-YL}ACETIC ACID |
| 4MDN | A: | STRUCTURE OF A NOVEL SUBMICROMOLAR MDM2 INHIBITOR |
| 4MDQ | A: | STRUCTURE OF A NOVEL SUBMICROMOLAR MDM2 INHIBITOR |
| 4OAS | A:; C:; E: | CO-CRYSTAL STRUCTURE OF MDM2 (17-111) IN COMPLEX WITH COMPOUND 25 |
| 4OBA | A:; B:; C: | CO-CRYSTAL STRUCTURE OF MDM2 WITH INHIBITOR COMPOUND 4 |
| 4OCC | A:; C:; E: | CO-CRYSTAL STRUCTURE OF MDM2(17-111) IN COMPLEX WITH COMPOUND 48 |
| 4ODE | A: | CO-CRYSTAL STRUCTURE OF MDM2 WITH INHIBITOR COMPOUND 4 |
| 4ODF | A: | CO-CRYSTAL STRUCTURE OF MDM2 WITH INHIBITOR COMPOUND 47 |
| 4OGN | A: | CO-CRYSTAL STRUCTURE OF MDM2 WITH INHBITOR COMPOUND 3 |
| 4OGT | A: | CO-CRYSTAL STRUCTURE OF MDM2 WITH INHBITOR COMPOUND 46 |
| 4OGV | A:; B:; C: | CO-CRYSTAL STRUCTURE OF MDM2 WITH INHIBITOR COMPOUND 49 |
)
)